Millennium Pharmaceuticals, Inc. (MLNM) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Millennium Pharmaceuticals, Inc. (MLNM)

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

From: idos	2/8/2007 8:51:37 AM
	Read Replies (1) of 3044

Despite tough competition from CELG, Velcade survives very nicely. Am I wrong? CHICAGO, Feb 8 (Reuters) - Millennium Pharmaceuticals Inc. (MLNM.O: Quote, Profile , Research) on Thursday posted a fourth-quarter profit versus a loss a year earlier, helped by increased sales of its cancer drug Velcade. The Cambridge, Massachusetts-based biotechnology company posted net profit of $8.3 million, or 3 cents per share, compared with a loss of $43.9 million, or 14 cents a share, a year earlier. Analysts on average expected earnings of 7 cents a share, according to Reuters Estimates. Quarterly revenue rose to $140.1 million from $122.3 million a year earlier. For 2007, the company expects earnings excluding special items of $10 million to $20 million. It forecast a 2007 net loss of between $60 million to $90 million. The difference is due to stock options expenses and other special items. It forecast Velcade sales in a range of $240 million to $260 million, compared to 2006 sales of $220.5 millio

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next